Community Update with Solid Biosciences on the New INSPIRE DUCHENNE Clinical Study of SGT-003
by: Parent Project Muscular Dystrophy
Solid Biosciences joined PPMD for a community webinar on December 6, 2023 to provide an overview of INSPIRE DUCHENNE, a first-in-human clinical study evaluating SGT-003, a next-generation microdystrophin gene therapy candidate for the treatment of Duchenne muscular dystrophy. During the webinar, members of Solid’s Clinical and Patient Advocacy teams shared details about SGT-003 and the INSPIRE DUCHENNE study.
by: Parent Project Muscular Dystrophy
![Webinar: PPMD Advocacy - Raising Our Voices in 2024 and Beyond [Sep 2024]](https://img.youtube.com/vi/sHbI1e3yNdw/maxresdefault.jpg)
